Researchers at the Helen F. Graham Cancer Center & Research Institute in Newark, Delaware have determined that use of Zometa, a drug used to treat bone cancer, reduces side effects in patients and increases cost savings wen administered every 3 months instead of monthly. This change in dosage has not resulted in increased risk of bone problems over a 2-year period. The study, conducted on more than 1800 patients with breast cancer, prostate cancer, or multiple myeloma indicated bone problems in 30% of patients who received the drug monthly compared to 29% who were administered the drug every 3 months.
To read more about this study, click here.
No comments:
Post a Comment